Syncona supplied a third of the investment and retains a majority stake in Freeline, which is based on research at UCL.

Freeline, a UK-based gene therapy spinout from University College London (UCL) formed by commercialisation firm Syncona, today closed a $120m series C round featuring the latter investor.
Pharmaceutical firm Novo Holdings, investment adviser Eventide Asset Management and investment management firm Wellington Management Company co-led the round, which also featured Cowen Healthcare Investments, Acorn Bioventures and Ample Plus Fund.
Syncona supplied $40m in a first tranche in December 2019 and retains a majority stake of 60%, down from 80%.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in